News
Investors take issue with Taisho Pharma’s buyout price
Two investment funds have decided to contest Taisho Pharma’s recently …
19707 items found
News
Germany inches closer to confidential pricing for drugs
Pharma companies who want to keep the prices of their medicines …
Market Access
Deepening perspectives: How social media is driving our understanding of HCP sentiment
On the 31st of May, news broke that the NHS was launching its …
News
UK’s Destiny Pharma hops on the AIM delisting train
Destiny Pharma has joined a growing list of UK biotechs seeking to …
News
Ozempic’s latest health benefit may be cutting dementia risk
Another week, and another study has emerged pointing to a way that …
News
Immutep mulls filings for LAG-3 drug after new readout
Shares in Immutep have leapt after the biotech reported phase 2b …
Oncology
News
Streeting orders “raw and frank” investigation of NHS
New UK Health Secretary Wes Streeting had only been in post a day …
R&D
Connecting the clinical, regulatory, and commercial dots for rare diseases
The path to rare disease product innovation involves …
News
Proposed Medicare codes could lift digital health sector
A new payment policy proposal released by the Centers for Medicare …
News
Pfizer selects once-daily GLP-1 for its obesity push
Pfizer is advancing on a broad front in its attempt to catch up with …
Digital
Coming soon: New EU Artificial Intelligence Act
Everyone is talking AI these days – and regulators are taking notice. …
News
France warns of penalties if Opella production goes offshore
Sanofi is now in exclusive talks with private equity company Clayton Dubilier & Rice over the sale of a controlling stake in its consumer health business Opella, as the French governmen
Sales & Marketing
Enabling site success: Key insights to reducing burden and i...
Investigator sites are essential for successful execution of clinical trials – ensuring studies are conducted ethically, safely, and in compliance with regulatory standards.
Sales & Marketing
Deep Dive: Commercialisation 2024
In this issue, we unpack Ozempic’s rise to superstar status and the risks associated with its off-label use.
Digital
Sponsored
How to deal with fragmented data - A $12.9 million challenge
In the age of AI, large data sets – like the treasure trove of customer data most biopharma companies are sitting on – are an invaluable asset.
Digital
Access to genomic surveillance: Open science and public heal...
The pandemic served as a catalyst for a revolution in genomic surveillance for tracking pathogens.
Sales & Marketing
Sponsored
Launch Excellence: Moments of Truth
The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns, creating challenges and opportunities.
R&D
Partner Content
BIO-Europe's 30th Anniversary Landmark Event in Stockholm
BIO-Europe™ celebrates 30 years of facilitating partnerships this Fall. In 1994, BIO-Europe launched with the mission to drive biotech innovation and
R&D
Partner Content
8th Dermatology Drug Development Summit
Industry’s Destination to Discover & Develop Best-In-Class Drugs for Immuno-Inflammatory Skin Disease
